Naftifine Hydrochloride Cream 2% + Naftin® (Naftifine Hydrochloride) Cream 2% + Placebo Topical Cream
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tinea Pedis
Conditions
Tinea Pedis
Trial Timeline
Aug 1, 2013 → Mar 1, 2014
NCT ID
NCT02132260About Naftifine Hydrochloride Cream 2% + Naftin® (Naftifine Hydrochloride) Cream 2% + Placebo Topical Cream
Naftifine Hydrochloride Cream 2% + Naftin® (Naftifine Hydrochloride) Cream 2% + Placebo Topical Cream is a phase 1 stage product being developed by Sun Pharmaceutical for Tinea Pedis. The current trial status is completed. This product is registered under clinical trial identifier NCT02132260. Target conditions include Tinea Pedis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02132260 | Phase 1 | Completed |
Competing Products
20 competing products in Tinea Pedis
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85